Vigest-KV
For the treatment of endometriosis.
Tabletki.ua
LIKI24
Information about medications intended exclusively for doctors and pharmacists.
INSTRUCTIONS
for medical use of the medicinal product
VIGEST-KV
(VIGEST-KV)
Composition:
active substance: dienogest;
1 tablet contains dienogest micronized 2 mg;
excipients: lactose, monohydrate; povidone K30; pregelatinized maize starch; magnesium stearate; microcrystalline cellulose; crospovidone (type A); colloidal anhydrous silica.
Pharmaceutical form. Tablets.
Basic physical and chemical properties: round white or slightly yellowish tablets, embossed with "D2" on one side and plain on the other side.
Pharmacotherapeutic group. Sex hormones and modulators of the genital system. Progestogens. Pregnadiene derivatives. Dienogest. ATC code G03D B08.
Pharmacological properties
Pharmacodynamics
Dienogest is a nortestosterone derivative with no androgenic activity and with some antiandrogenic activity, which is approximately one-third of that of cyproterone acetate. Dienogest binds to the progesterone receptors of the human uterus with only 10 % relative affinity. Despite its low affinity for the progesterone receptor, dienogest has a strong progestogenic effect in vivo. Dienogest does not have any significant androgenic, mineralocorticoid or glucocorticoid activity in vivo.
Dienogest acts on endometriosis by reducing the endogenous production of estradiol and thereby suppressing the trophic effects of estradiol on both the eutopic and ectopic endometrium. When given continuously, dienogest leads to a hypoestrogenic, hypergestagenic endocrine environment, causing initial decidualization of endometrial tissue followed by atrophy of endometriotic lesions.
Efficacy data. The superiority of dienogest 2 mg over placebo with respect to endometriosis-associated pelvic pain was demonstrated in a 3-month study that included 198 patients with endometriosis. Endometriosis-associated pelvic pain was measured on a Visual Analogue Scale (0−100 mm). After 3 months of treatment with dienogest 2 mg, a statistically significant difference compared with placebo (D = 12.3 mm; 95 % confidence interval (CI): 6.4–18.1; p < 0.0001) and a clinically meaningful reduction of pain compared with baseline were demonstrated (mean reduction of 27.4 ± 22.9 mm).
After 3 months of treatment, a reduction of endometriosis-associated pelvic pain by 50 % or more without a relevant increase of concomitant analgesic medication was achieved in 37.3 % of patients receiving dienogest 2 mg (placebo: 19.8 %); a reduction of endometriosis-associated pelvic pain by 75 % or more (also without a relevant increase of concomitant analgesic medication) was achieved in 18.6 % of patients receiving dienogest 2 mg (placebo: 7.3 %).
The open-label extension of this study showed a continued reduction of endometriosis-associated pelvic pain with treatment of up to 15 months' duration.
The results of the placebo-controlled studies were supported by the results obtained in a 6-month active-controlled study versus a gonadotropin-releasing hormone agonist that included 252 patients with endometriosis.
Three studies that included 252 patients receiving dienogest 2 mg daily demonstrated a substantial reduction of endometriotic lesions after 6 months of treatment.
In a small study (n = 8 per dose group), dienogest at a dose of 1 mg daily showed an absence of ovulation after 1 month of therapy. Dienogest 2 mg has not been studied for contraceptive efficacy in larger studies.
Safety data. The level of endogenous estrogen is only moderately suppressed during treatment with dienogest 2 mg.
To date, there are no long-term data on bone mineral density (BMD) and fracture risk in patients using dienogest 2 mg. BMD was assessed in 21 adult patients before and after 6 months of treatment with dienogest 2 mg. No decrease in mean BMD was detected. In 29 patients treated with leuprorelin acetate, a mean decrease of 4.04 ± 4.84 % was observed over the same period (D between groups was 4.29 %, 95 % CI: 1.93−6.66, p < 0.0003).
No significant effect on standard laboratory parameters, including haematology, blood chemistry, liver enzymes, lipids and HbA1C, was observed during treatment with dienogest 2 mg for up to 15 months (n = 168).
Safety data in adolescents. The safety of dienogest 2 mg with respect to BMD was studied in a 12-month clinical study in 111 adolescent patients (aged 12 to <18 years) with clinically suspected or confirmed endometriosis. The mean relative change in lumbar spine (L2–L4) BMD from baseline in 103 patients by the end of treatment was –1.2 %. A repeat measurement 6 months after the end of treatment in a subgroup with decreased BMD values showed an increase in BMD to –0.6 %.
Preclinical safety data. Preclinical data reveal no special hazard for humans based on conventional studies of repeated-dose toxicity, genotoxicity, carcinogenic potential and toxicity to reproduction. However, it should be borne in mind that sex steroids may promote the growth of certain hormone-dependent tissues and tumours.
Long-term safety data. An observational post-authorization active surveillance study was conducted to determine the incidence of new-onset or worsening of clinically significant depression and the occurrence of anaemia. A total of 27,840 women who were prescribed hormonal therapy for the treatment of endometriosis for the first time were enrolled in the study and were followed for up to 7 years. Dienogest 2 mg was prescribed to 3023 women, and 3371 patients were prescribed other medicinal products approved for the treatment of endometriosis. The overall adjusted hazard ratio for new-onset anaemia in patients taking dienogest compared with patients taking other medicinal products approved for the treatment of endometriosis was 1.1 (95 % CI: 0.4–2.6). The adjusted hazard ratio for depression in patients taking dienogest compared with patients taking other medicinal products approved for the treatment of endometriosis was 1.8 (95 % CI: 0.3–9.4). A slightly increased risk of depression in patients taking dienogest compared with patients taking other medicinal products approved for the treatment of endometriosis cannot be excluded.
Pharmacokinetics
Absorption. After oral administration, dienogest is rapidly and almost completely absorbed. The maximum serum concentration is reached within 1.5 hours after a single oral dose and amounts to 47 ng/mL. The bioavailability of dienogest is approximately 91 %. The pharmacokinetics of dienogest are dose-proportional in the dose range of 1−8 mg.
Distribution. Dienogest binds to serum albumin and does not bind to sex hormone-binding globulin (SHBG) or corticoid-binding globulin (CBG). Only 10 % of the total serum concentration of dienogest is present as free steroid, while 90 % is non-specifically bound to albumin. The apparent volume of distribution of dienogest is 40 L.
Metabolism. Dienogest is completely metabolized by the known pathways of steroid metabolism, with the formation of mainly endocrinologically inactive metabolites. According to in vitro and in vivo studies, CYP3A4 is the main enzyme involved in the metabolism of dienogest. These metabolites are eliminated from plasma very rapidly, so unchanged dienogest remains the main compound in plasma.
Plasma clearance is 64 mL/min.
Elimination. The serum level of dienogest decreases in two phases, with a half-life of 9-10 hours. Dienogest is excreted in the form of metabolites with urine and faeces at a ratio of approximately 3:1 after oral administration of a dose of 0.1 mg/kg. The half-life of urinary metabolites is approximately 14 hours. After oral administration, 86 % of the administered dose is eliminated from the body within 6 days, with the major part of this amount excreted during the first 24 hours, mainly with urine.
Steady state. The pharmacokinetics of dienogest are not influenced by SHBG levels. With daily intake, the serum concentration of the substance increases by a factor of 1.24, reaching steady state after 4 days of use. The pharmacokinetics of dienogest after repeated administration can be predicted from the pharmacokinetics of a single dose.
Pharmacokinetics in special patient groups. The pharmacokinetics of dienogest have not been studied in patients with renal impairment.
The pharmacokinetics of dienogest have not been studied in patients with hepatic impairment.
Clinical particulars
Indications. For the treatment of endometriosis.
Contraindications
Vigest-KV should not be used in the presence of any of the conditions or diseases listed below. This information is partly derived from the use of other progestogen-only preparations. If any of these conditions or diseases appears for the first time during the use of Vigest-KV, the drug should be discontinued immediately.
- Active venous thromboembolism (VTE).
- Present or past arterial or cardiovascular disease (e.g. myocardial infarction, cerebrovascular event, ischaemic heart disease).
- Diabetes mellitus with vascular involvement.
- Present or past severe liver disease, until liver function values have returned to normal.
- Present or past liver tumours (benign or malignant).
- Known or suspected sex hormone-dependent malignancies.
- Undiagnosed vaginal bleeding.
- Hypersensitivity to the active substance or to any of the excipients of the medicinal product.
Interaction with other medicinal products and other forms of interaction
Note: the instructions for medical use of concomitantly used medicinal products should be consulted in order to identify potential interactions.
Effects of other medicinal products on Vigest-KV
Progestogens, including dienogest, are metabolized mainly by the cytochrome P450 3A4 system (CYP3A4) located in the intestinal mucosa and in the liver. Therefore, inducers or inhibitors of CYP3A4 may affect the metabolism of progestogen. Increased clearance of sex hormones due to enzyme induction may reduce the therapeutic effect of Vigest-KV and may result in undesirable effects, e.g. changes in the menstrual bleeding pattern.
Decreased clearance of sex hormones due to enzyme inhibition may reduce the therapeutic effect of Vigest-KV and may lead to the development of adverse reactions.
- Substances increasing the clearance of sex hormones (reduced efficacy through enzyme induction), e.g.: phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin and products containing St. John's wort (Hypericum perforatum).
Enzyme induction can be observed after a few days of treatment. Maximum enzyme induction is generally seen within a few weeks.
Enzyme induction may persist for up to 4 weeks after the cessation of therapy.
The effect of the CYP3A4 inducer rifampicin was studied in healthy postmenopausal women. Concomitant administration of rifampicin with estradiol valerate / dienogest tablets resulted in a significant decrease in the steady-state concentrations and systemic exposure of dienogest and estradiol. The systemic exposure of dienogest and estradiol at steady state, measured by AUC (0–24 hours), was decreased by 83 % and 44 %, respectively.
- Substances with variable effects on the clearance of sex hormones.
When co-administered with sex hormones, many combinations of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, including combinations with hepatitis C virus inhibitors, can increase or decrease plasma concentrations of progestin. The net effect of these changes may be clinically relevant in some cases.
- Substances decreasing the clearance of sex hormones (enzyme inhibitors).
Dienogest is a substrate of cytochrome P450 (CYP) 3A4.
The clinical relevance of potential interactions with enzyme inhibitors remains unknown.
Concomitant administration of strong CYP3A4 inhibitors may increase plasma concentrations of dienogest.
Concomitant administration with the strong CYP3A4 inhibitor ketoconazole led to a 2.9-fold increase in the steady-state AUC (0–24 hours) of dienogest. Concomitant administration with the moderate inhibitor erythromycin led to a 1.6-fold increase in the steady-state AUC (0–24 hours) of dienogest.
Effects of dienogest on other medicinal products
Based on in vitro inhibition studies, a clinically relevant interaction of dienogest with other drugs whose metabolism is mediated by cytochrome P450 enzymes is unlikely.
Interaction with food
A high-fat meal did not affect the bioavailability of Vigest-KV.
Laboratory tests
The use of progestogens may influence the results of certain laboratory tests, including biochemical parameters of the liver, thyroid, renal and adrenal function, plasma levels of (carrier) proteins (e.g. CBG and lipid/lipoprotein fractions), parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.
Special warnings and precautions for use
Warnings
Since Vigest-KV is a progestogen-only medicinal product, it is assumed that the special warnings and precautions for the use of progestogen-containing medicinal products also apply to Vigest-KV, although not all warnings and precautions are based on corresponding findings from studies of this particular medicinal product.
If any of the conditions/risk factors mentioned below worsens or appears for the first time, an individual risk/benefit analysis should be performed before starting or continuing treatment with Vigest-KV.
Severe uterine bleeding
Uterine bleeding, e.g. in women with uterine adenomyosis or uterine leiomyomata, may be aggravated by the use of Vigest-KV. If bleeding is heavy and continues over a long period of time, it may lead to anaemia (severe in some cases). In such a case, discontinuation of the medicinal product should be considered.
Change in bleeding pattern
Most patients taking dienogest 2 mg experience a change in the menstrual bleeding pattern (see the section "Adverse reactions").
Circulatory disorders
Epidemiological studies have provided some evidence of an association between the use of progestogen-only preparations and an increased risk of myocardial infarction or cerebral thromboembolism. The risk of cardiovascular and cerebral events is rather related to age, arterial hypertension and smoking. In women with hypertension, the risk of stroke may be slightly increased by the use of progestogen-only preparations.
Some studies indicate a certain, statistically non-significant, increase in the risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism) associated with the use of progestogen-only preparations. Generally recognized risk factors for venous thromboembolism (VTE) include: a personal or family history of VTE (e.g. VTE in a sibling or parent at a relatively early age), older age, obesity, prolonged immobilization, major surgery or trauma. In the case of prolonged immobilization, it is recommended to discontinue the use of Vigest-KV (in the case of elective surgery at least 4 weeks before it) and not to resume treatment earlier than 2 weeks after complete remobilization.
The increased risk of thromboembolism in the postpartum period should be borne in mind.
Treatment should be discontinued immediately if symptoms of venous or arterial thrombotic events occur or are suspected.
Tumours
A meta-analysis of epidemiological studies indicates a slightly increased relative risk (RR = 1.24) of breast cancer diagnosed in women who are using oral contraceptives (OCs), mainly those containing estrogen-progestogen. This increased risk gradually disappears within 10 years after cessation of combined oral contraceptives (COCs). Because breast cancer is rare in women under 40 years of age, the increase in the number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. The risk of breast cancer diagnosed in women taking progestogen-only preparations is similar to that associated with COCs. However, for progestogen-only preparations, the evidence is based on much smaller populations of users and is therefore less conclusive than that for COCs. These studies do not provide evidence of causality. The observed increased risk may be due to earlier diagnosis of breast cancer in OC users, the biological effects of OCs, or a combination of both. There is a tendency for breast cancer diagnosed in ever-users of OCs to be clinically less advanced than in never-users.
In rare cases, benign liver tumours, and even more rarely malignant liver tumours, have been observed in women using hormonal substances similar to that contained in Vigest-KV; in isolated cases these have led to life-threatening intra-abdominal haemorrhage. If severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur, a liver tumour should be considered in the differential diagnosis in women taking Vigest-KV.
Osteoporosis
Changes in bone mineral density (BMD).
The use of dienogest 2 mg in adolescents (12–18 years) over a 12-month treatment period was associated with a decrease in mean lumbar spine (L2–L4) BMD of 1.2 %. After discontinuation of treatment, BMD increased again in these patients.
The mean relative change in BMD from baseline to the end of treatment was 1.2 %, with a range between –6 % and 5 % (95 % CI: –1.70 % and –0.78 %, n = 103). A repeat measurement 6 months after the end of treatment in a subgroup with decreased BMD values showed a tendency towards recovery (mean relative change from baseline: –2.3 % at the end of treatment and –0.6 % 6 months after the end of treatment, with a range between –9 % and 6 % [95 % CI: –1.20 % and 0.06 % (n = 60)].
Impairment of bone mineral density is of particular concern during adolescence and early adulthood, a critical period of bone growth. It is not known whether a decrease in BMD in this population will reduce peak bone mass and increase the risk of fracture in later life (see the sections "Children" and "Pharmacological properties").
Before starting treatment, the physician should weigh the benefits of using Vigest-KV against the possible risks for each individual adolescent, also taking into account the presence of significant risk factors for osteoporosis.
Adequate intake of calcium and vitamin D, whether from diet or from supplements, is important for bone health in women of all ages.
No decrease in BMD was observed in adults (see the section "Pharmacodynamic properties").
In patients at increased risk of osteoporosis, a careful assessment of the risk/benefit ratio should be performed before starting treatment with Vigest-KV, since endogenous estrogen levels are moderately decreased during treatment (see the section "Pharmacodynamics").
Other conditions
Patients with a history of depression should be carefully monitored, and the medicinal product should be discontinued if marked symptoms of depression develop.
Dienogest does not generally affect blood pressure in normotensive women. However, if sustained, clinically significant hypertension develops during the use of the medicinal product, it is recommended to discontinue Vigest-KV and treat the hypertension.
Use of Vigest-KV should be discontinued upon recurrence of cholestatic jaundice and/or pruritus that first occurred during pregnancy or previous use of sex hormones.
Dienogest may have a slight effect on peripheral insulin resistance and glucose tolerance. Women with diabetes mellitus, especially those with a history of gestational diabetes mellitus, should be carefully monitored during the use of Vigest-KV.
Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to direct sunlight or ultraviolet radiation while taking Vigest-KV.
The likelihood of ectopic pregnancy is higher in women using progestogen-only preparations for contraception than in women using COCs. Therefore, in women with a history of ectopic pregnancy or impaired fallopian tube function, the question of using Vigest-KV should be decided only after a careful assessment of the benefit/risk ratio.
Persistence of follicles (often described as functional ovarian cysts) may occur during the use of Vigest-KV. Most of these follicles are asymptomatic, although some may be accompanied by pelvic pain.
Lactose
This medicinal product contains lactose; therefore, patients with rare hereditary conditions such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not use it.
Use during pregnancy or breast-feeding
Pregnancy. Data on the use of dienogest in pregnant women are limited. Animal studies do not indicate direct or indirect risks of reproductive toxicity (see the section "Pharmacological properties").
Vigest-KV is not recommended for use in pregnant women because there is no need to treat endometriosis during pregnancy.
Breast-feeding. Treatment with Vigest-KV during breast-feeding is not recommended. It is not known whether dienogest passes into human breast milk. Data obtained in animal studies indicate that dienogest passes into breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue therapy with Vigest-KV, taking into account the benefit of breast-feeding for the child and the need for therapy for the woman.
Fertility. Based on the available data, ovulation is inhibited in the majority of patients during treatment with Vigest-KV. However, Vigest-KV is not a contraceptive.
If contraception is required, an additional non-hormonal method of preventing pregnancy should be used (see the section "Method of administration and doses").
Based on the available data, the menstrual cycle returns to normal within 2 months after discontinuation of treatment with Vigest-KV.
Ability to influence reaction speed when driving or operating other mechanisms. No effects on the ability to drive or operate other machinery were observed in patients taking medicinal products containing dienogest.
Method of administration and doses
Method of administration
The medicinal product is for oral use.
Dosage
Take 1 tablet daily without a break, at approximately the same time each day, with a small amount of liquid. The tablets can be taken irrespective of meals.
The tablets should be taken regularly, regardless of menstrual bleeding. When the tablets from one pack have been finished, begin the next pack without a break in the use of the medicinal product.
Treatment can be started on any day of the menstrual cycle.
Any hormonal contraceptives should be discontinued before starting therapy with Vigest-KV. If contraception is required, an additional non-hormonal method of preventing pregnancy (e.g. a barrier method) should be used.
Missed dose
The efficacy of Vigest-KV may be reduced in the event of a missed tablet, vomiting and/or diarrhoea (occurring within 3−4 hours after taking a tablet). In the event of one or more missed tablets, 1 tablet should be taken as soon as the woman remembers, and the next tablet should be taken at the usual time. A tablet that has not been absorbed because of vomiting or diarrhoea should likewise be replaced with another tablet.
Use in special patient groups
Elderly patients
There is no relevant indication for the use of Vigest-KV in patients of this group.
Hepatic impairment
The medicinal product is contraindicated in patients with present or past severe liver disease (see the section "Contraindications").
Renal impairment
There are no data suggesting the need for dose adjustment in patients with renal impairment.
Children
Vigest-KV is not indicated for use in children before menarche.
The safety and efficacy of dienogest 2 mg were studied in a 12-month uncontrolled study in 111 adolescent patients (12–<18 years) with clinically suspected or confirmed endometriosis (see the sections "Special warnings and precautions for use" and "Pharmacological properties").
The efficacy of dienogest 2 mg was demonstrated in the treatment of endometriosis accompanied by pelvic pain in adolescents (12–18 years), with an overall favourable safety and tolerability profile of the medicinal product.
The use of dienogest 2 mg for 12 months in adolescents led to a decrease in mean bone mineral density (BMD) in the lumbar spine of 1.2 %. After discontinuation of treatment, BMD increased again in these patients.
Changes in bone mineral density are of particular importance in adolescence and early adulthood, a critical stage of bone growth. It is not known whether a decrease in BMD in this population will affect the formation of peak bone mass and increase the risk of fracture in later life.
Therefore, the physician should weigh the benefits of using Vigest-KV against the possible risks for each individual adolescent (see the sections "Special warnings and precautions for use" and "Pharmacodynamic properties").
Overdose
Acute toxicity studies performed with dienogest did not indicate a risk of acute adverse reactions following inadvertent intake of several times the daily therapeutic dose. There are no specific antidotes. At 20−30 mg of dienogest per day (10 to 15 times higher than the dose in a Vigest-KV tablet) for more than 24 weeks, the medicinal product was very well tolerated.
Adverse reactions
Adverse reactions are described according to MedDRA [Medical Dictionary for Regulatory Activities].
Adverse reactions most often develop during the first months after the start of Vigest-KV treatment and subside during treatment. Changes in the menstrual bleeding pattern, such as spotting, irregular bleeding or amenorrhoea, may be observed.
The adverse reactions most frequently reported during treatment with dienogest 2 mg are headache (9.0 %), breast discomfort (5.4 %), depressed mood (5.1 %) and acne (5.1 %).
In addition, most patients receiving dienogest 2 mg experienced a change in the menstrual bleeding pattern. The menstrual bleeding pattern was assessed systematically using patient diaries and analysed using the WHO 90-day reference period method. During the first 90 days of treatment with dienogest 2 mg, the following bleeding patterns were observed (n = 290; 100 %): amenorrhoea (1.7 %), infrequent bleeding (27.2 %), frequent bleeding (13.4 %), irregular bleeding (35.2 %), prolonged bleeding (38.3 %), normal menstrual bleeding, i.e. none of the previous categories (19.7 %). During the fourth reference period, the following bleeding patterns were observed (n = 149; 100 %): amenorrhoea (28.2 %), infrequent bleeding (24.2 %), frequent bleeding (2.7 %), irregular bleeding (21.5 %), prolonged bleeding (4.0 %), normal menstrual bleeding, i.e. not belonging to any of the previous categories (22.8 %). Changes in the menstrual bleeding pattern were only occasionally described by patients as adverse reactions.
The adverse reactions reported during treatment with dienogest and their frequencies are listed below. Within each system organ class, adverse effects are listed in order of decreasing frequency: common (from ≥ 1/100 to <1/10) and uncommon (from ≥ 1/1000 to <1/100). The frequency is based on pooled data from four clinical studies involving 332 patients (100 %).
Blood and lymphatic system disorders: uncommon — anaemia.
Metabolism and nutrition disorders: common — weight increased; uncommon — weight decreased, increased appetite.
Psychiatric disorders: common — depressed mood, sleep disorders, nervousness, loss of libido, mood changes; uncommon — anxiety, depression, mood swings.
Nervous system disorders: common — headache, migraine; uncommon — autonomic nervous system imbalance, disturbance in attention.
Eye disorders: uncommon — dry eye.
Ear and labyrinth disorders: uncommon — tinnitus.
Cardiac disorders: uncommon — unspecified circulatory system disorders, palpitations.
Vascular disorders: uncommon — hypotension.
Respiratory, thoracic and mediastinal disorders: uncommon — dyspnoea.
Gastrointestinal disorders: common — nausea, abdominal pain, flatulence, abdominal distension, vomiting; uncommon — diarrhoea, constipation, abdominal discomfort, gastrointestinal inflammation, gingivitis.
Skin and subcutaneous tissue disorders: common — acne, alopecia; uncommon — dry skin, hyperhidrosis, pruritus, hirsutism, onychoclasis, dandruff, dermatitis, abnormal hair growth, photosensitivity reaction, pigmentation disorder.
Musculoskeletal and connective tissue disorders: common — back pain; uncommon — bone pain, muscle spasms, pain in extremity, heaviness in extremities.
Renal and urinary disorders: uncommon — urinary tract infection.
Reproductive system and breast disorders: common — breast discomfort, ovarian cyst, hot flushes, uterine/vaginal bleeding, including spotting; uncommon — vaginal candidiasis, vulvovaginal dryness, genital discharge, pelvic pain, atrophic vulvovaginitis, breast mass, fibrocystic breast disease, breast induration.
General disorders and administration site conditions: common — asthenic conditions, irritability; uncommon — oedema.
The following adverse reactions were also observed: persistence of follicles, increased appetite, hypersensitivity reactions.
During the use of steroidal sex hormones, progestogens, other serious adverse reactions have been observed (see the section "Special warnings and precautions for use"): venous and arterial thromboembolic disorders, arterial hypertension, myocardial infarction, stroke, breast neoplasms, liver tumours, back discomfort, chloasma, cholestatic jaundice, osteoporosis (see below), changes in glucose tolerance or effects on peripheral insulin resistance.
Decrease in bone mineral density
In studies involving 111 adolescent patients (aged 12 to <18 years) treated with dienogest 2 mg, BMD was measured in 103 patients. In approximately 72 % of study participants, a decrease in lumbar spine (L2–L4) BMD was observed after 12 months of use (see the section "Special warnings and precautions for use").
Reporting of suspected adverse reactions
Reporting of adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of this medicinal product. Healthcare professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of the medicinal product through the Automated Pharmacovigilance Information System at: https://aisf.dec.gov.ua.
Shelf life. 3 years.
Storage conditions
Store in the original package at a temperature not exceeding 30 °C.
Keep out of the reach of children.
Package. 28 tablets in a blister; 1 blister in a carton.
Dispensing category. By prescription.
Manufacturer
1. JSC "KYIV VITAMIN PLANT".
2. Sindea Pharma, S.L.
Location of the manufacturer and address of its place of business
1. 04073, Ukraine, Kyiv, 38 Kopylivska St.
2. Polígono Industrial Emiliano Revilla Sanz. Avenida de Ágreda, 31, Ólvega, 42110 Soria, Spain.
Date of last revision. 14.10.2026
Information about medications intended exclusively for doctors and pharmacists.